Cutanos GmbH

The skin is the human body's largest organ and, for centuries, was regarded primarily as a barrier. Modern precision medicine sees it differently: as a privileged gateway to the immune system, through Langerhans cells — immunological sentinels residing in the outer layers of the epidermis. It is on this insight that Cutanos, a deep-tech startup, has built its core technology: a system for targeted delivery of therapies directly to these cells. Cutanos's flagship product is the LC-TDS (Langerhans Cell-Targeted Delivery System), a technology designed to selectively deliver vaccines, immunotherapies, and other biological agents to Langerhans cells via the skin, as an alternative to conventional injections. This approach is not merely more convenient — it may prove more effective, because Langerhans cells are among the most powerful mediators of the adaptive immune response. The business model is B2B, with customized solutions developed for pharmaceutical companies, biotech firms, and research centers engaged in vaccine and immunotherapy development. Cutanos does not independently produce finished therapies; instead, it offers its delivery platform as an enabling technology for partners seeking to improve the efficacy or tolerability of their own pipeline assets. This platform-as-enabler approach positions the company as a transversal technology partner across multiple therapeutic pipelines. The drug delivery systems market is growing rapidly, driven by surging demand for biologics that require innovative administration routes. Immunotherapy — in oncology, allergy, and autoimmune disease — is one of the fastest-developing areas in pharmaceuticals, and the ability to modulate immune response through the cutaneous route could represent a meaningful competitive advantage for Cutanos's partners. Precision medicine, starting from the outermost layer of the body.